Ablative Solutions Inc.
Targeted renal denervation
This article was originally published in Start Up
Executive Summary
Unlike other renal denervation technologies that apply destructive energy to the entire renal artery wall, , Ablative Solutions Inc. has developed a catheter-based approach that delivers ethanol directly to the nerves that encircle the renal artery, and destroys them without damaging the artery walls . The company is developing its Peregrine System for use in an outpatient setting to restore normal blood pressure in medication-resistant hypertensive patients.
You may also be interested in...
A Device For Hypertension After All?
Despite industry-wide contraction last year after Medtronic's SYMPLICITY, some believe a hypertension device is just around the corner. With a market estimated in the billions or even tens of billions of dollars, both Medtronic and Boston Scientific are launching redesigned studies, and a determined handful of medtech start-ups continue to pursue a device-based solution for treating hypertension with invasive and noninvasive approaches, including renal sympathetic denervation through radiofrequency, ultrasound, or drugs; neuromodulation in the forearm; and cold therapy to specialized cells in the neck.
A Device For Hypertension After All?
Despite industry-wide contraction last year after Medtronic's SYMPLICITY, many agree the trial was flawed, and some believe a hypertension device is just around the corner. A determined handful of medtech start-ups continue to pursue a device-based approach, most by reducing “fight-or-flight” outflow from the sympathetic nervous system.
Renal Denervation: Device Market’s Gold Rush
Three years ago, only Ardian was publicly working on renal denervation devices for hypertension, but at last month’s ACC meeting, some said there were now anywhere from 16 to 40 companies in the space. Fast followers don’t want to miss out on an IP land grab in today’s hottest medical device space.